PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA

Transcription

1 PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA 9:00 9:15 AM Welcome and Introductions TUESDAY, DECEMBER 15, :00 AM 5:05 PM 9:15 9:45 AM Update on the Ryan White HIV/AIDS Program Laura W. Cheever, MD Associate Administrator Chief Medical Officer HIV/AIDS Bureau Health Resources and Services Administration Rockville, MD 9:45 9:55 AM Question-and-Answer Period 9:55 10:25 AM When Will We Have a Cure and What Will It Look Like? This presentation will discuss different perspectives of Cure research. Robert F. Siliciano, MD, PhD Director of the MD/PhD Program The Johns Hopkins University School of Medicine Baltimore, MD 10:25 10:35 AM Question-and-Answer Period 10:35 10:55 AM Break 10:55 11:25 AM A Shot in the Arm for HIV Prevention? Opportunities & Challenges in :25 11:45 AM Panel Discussion Jeanne M. Marrazzo, MD, MPH Acting Head, Division of Allergy and Infectious Diseases University of Washington Medical Director Seattle STD/HIV Prevention Training Center Seattle, Washington 11:45 AM 12:15 PM State-of-the-Art in Antiretroviral Management This didactic presentation will discuss antiretroviral therapy, including the START data, what to start, and investigational new drugs/formulations. In addition, this presentation will address starting and switching and current antiretroviral dilemmas. Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct The Johns Hopkins University School of Medicine Baltimore, Maryland 12:15 PM 12:25 PM Question-and-Answer Period

2 12:25 1:55 PM LUNCH ON OWN (1.5 hours) AFTERNOON 1:55 2:25 PM Renal Disease in HIV Infection This presentation will focus on renal dysfunction and renal toxicities in patients with HIV-infection. Christina M. Wyatt, MD Assistant Division of Nephrology Mount Sinai School of Medicine New York, New York 2:25 2:35 PM Question-and-Answer Period 2:35 3:05 PM Cardiovascular Complications of HIV and Its Treatment This presentation will discuss cardiovascular disease (CVD) risk, guidelines for statin use, tenofovir and TAF risk overview. Marshall Glesby, MD, PhD, Healthcare Policy and Research Associate Chief, Medical Director, Cornell HIV Clinical Trials Unit Weill Cornell Medical College New York, New York 3:05 3:15 PM Question-and-Answer Period 3:15 3:45 PM Neurologic Complications of HIV This presentation will discuss neurocognitive issues in HIV-infected patients. Specifically, how to review assessments in the office, when to initiate treatment for neurologic complications, and in the absence of neuropsychological testing (NPT), what are your next steps. Victor G. Valcour, MD Division of Geriatrics and Department of Neurology Department of Medicine San Francisco, CA 3:45 3:55 PM Question-and-Answer Period 3:55 4:15 PM Break 4:15 5:15 PM 3 Concurrent Workshops What Clinicians Should Know About HCV Michael S. Saag, MD PrEP and PEP in the Real World: Magic Pills and Unintended Consequences Jeanne M. Marrazzo, MD, MPH In this session we will explore the current status of PrEP and PEP implementation in various settings, from Ryan White care settings to STD clinics and primary care. Topics for discussion will include dosing strategies for intermittent use, attention to challenges unique to women using PrEP, and transitioning from PEP to PrEP, as well as the potential for PEP/PrEP users to acquire more non-hiv sexually transmitted infections if the rate of condom use declines. What Do I Do With A Patient I Don t Know What To Do With? A Guide to the Clinically Perplexed Glenn J. Treisman, MD, PhD

3 WEDNESDAY, DECEMBER 16, :00 AM 4:40 PM 9:00 9:30 AM Persistent Challenges of HIV Transmission Control in Injection Drug Use: Lessons From The Indiana Outbreak Diane M. Janowicz, MD Assistant Professor of Clinical Medicine Indiana University School of Medicine Indianapolis, Indiana 9:30 9:40 AM Question-and-Answer Period 9:40 10:10 AM Elements of the Care Continuum This presentation will address the elements of the care continuum including testing, engagement, treatment and retention in care challenges. In addition, this presentation will practical advice and techniques to improve outcomes and retention to care. Michael J. Mugavero, MD Associate 10:10 10:20 AM Question-and-Answer Period 10:20 10:40 AM Break 10:40 11:10 AM Sexually-Transmitted Infections This presentation will focus on the revised STD guidelines. Kimberly A. Workowski, MD, FACP, FIDSA Emory University Atlanta, GA 11:10 11:20 AM Question-and-Answer Period 11:20 AM 12:50 PM LUNCH ON OWN (1.5 hours) AFTERNOON 12:50 1:50 PM Antiretroviral Therapy: Challenging Cases in Audience Interactive- Panel Discussion Michael S. Saag, MD Associate Dean for Global Health, School of Medicine 1:50 2:00 PM Question-and-Answer Period 2:00 2:30 PM Chronic Pain in Patients with HIV: What Clinicians Need to Know This presentation will discuss chronic pain as a serious chronic illness associated with important health consequences, identify what is known about chronic pain in HIV-infect patients, and describe a clinical approach to the evaluation and management of HIV-infected patients with chronic pain.

4 Jessica S. Merlin, MD Assistant Professor Division of Gerontology, Geriatrics, and Palliative Care 2:30 2:40 PM Question-and-Answer Period 2:40 3:10 PM Get Your HIV/AIDS Patients to Stop Smoking Before it Kills Them This presentation will discuss current approaches to assist patients in stopping smoking. Steven Schroeder, MD Professor of Health and Healthcare San Francisco, California 3:10 3:20 PM Question-and-Answer Period 3:20 3:40 PM Break 3:40 4:40 PM 3 Concurrent Workshops Antiretroviral Therapy: Cases from the Clinicians Joel E. Gallant, MD, MPH Issues in HCV Management David L. Wyles, MD Long-Term Opioid Therapy in Individuals with Chronic Pain: A Case-Based Discussion Jessica S. Merlin, MD This session will begin by briefly reviewing the current state of the science regarding long-term opioid prescribing. We will use a risk/benefit framework to discuss decisions about initiation and continuation of opioids. Then, we will review behaviors that may arise among individuals on longterm opioid therapy. These include using more opioid than prescribed, unhealthy use of alcohol or illicit drugs, missing appointments, and aggressive behavior, among others. Using a case-based approach, we will discuss the approach to evaluation and management of these behaviors. THURSDAY, DECEMBER 17, :00 AM 11:35 AM 9:00 9:40 AM Strategies for Staying Current in HIV Care Panel Discussion Steven Bromer, MD Clinical Professor San Francisco, California 9:40 9:50 AM Question-and-Answer Period 9:50 10:20 AM State of the Art in Hepatitis C Virus Infection in HIV/HCV Coinfected Patients This presentation will discuss who should be treated, staging liver disease, what to use, important interactions between direct-acting antivirals (DAAs) and antiretrovirals, and new drugs in development. David L. Wyles, MD Associate University of California San Diego La Jolla, California 10:20 10:35 AM Question-and-Answer Period

5 10:35 10:55 AM Break 10:55 11:25 AM What I Have Learned in 25 Years of HIV and Hepatitis C Psychiatry This presentation will address mental illness, personality disorders, substance abuse, and opiate seekers, and the behavioral and psychological approaches to managing these patients. Glenn J. Treisman, MD, PhD Eugene Meyer III Professor of Psychiatry and Medicine Director, AIDS Psychiatry Service The Johns Hopkins Medical Institutions Baltimore, Maryland 11:25 11:35 AM Question-and-Answer Period